Bluebird Bio to Be Acquired by Carlyle Group, SK Capital
Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital ...
Ariel Investments Small/Mid Cap Value Q4 2024 Commentary
Markets worldwide defied expectations in 2024 led by the dominating performance of mega-cap technology stocks known as the ...
Big 4 Private Equity Firms In Brighter Mood; Falling Investment In Biotech
Private equity fundraising struggled in 2024, with total capital raised declining for the third consecutive year. Read more ...
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
Moneyweb14h
Fund giant BlackRock is out to unite public and private markets
They invest in public stocks and bonds, and their clients are increasingly sensitive to costs. Their most popular products these days are passive index trackers with razor-thin fees, often just a few ...
Struggling Somerville biotech Bluebird Bio to be sold for less than $30 million
Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...
The Pharma Letter23h
Private equity firms put bluebird bio out of its misery
Once the hottest property in biotech, gene therapy company bluebird bio has been sold for less than $500 million after a long series of setbacks.
Boston group hoping to land a WNBA franchise. The league has said it will add a 16th team in 2028
Former NBA player Michael Carter-Williams is hoping to get a WNBA franchise in Boston whether it’s through expansion or ...